Genzyme's Gaucher disease drug hits main goals in 2 Phase III trials

02/18/2013 | Reuters · Fox Business

Eliglustat tartrate, an experimental drug from Sanofi unit Genzyme, met the primary goals of two late-stage trials involving patients with Gaucher disease. Eliglustat was associated with reductions in spleen size and matched Sanofi's Cerezyme in symptom response. The company plans to use the trials in seeking regulatory approval.

View Full Article in:

Reuters · Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ